At Thermo Fisher Scientific, we understand the complexities and challenges that biotech and pharmaceutical companies face when developing biologics. From early-stage development to full-scale clinical commercialization, our comprehensive cell line development (CLD) services are designed to streamline every step of your biologics journey. With over 120 PD programs executed from 2017 to present, we are confident that our dedicated team of experts can help take your program from concept to reality and help to ensure a smooth transition from development to GMP manufacturing with an efficient time-to-market and regulatory compliance.
We offer expert-driven CLD, leveraging cutting-edge technologies such as AI- and ML-based gene and vector sequence optimization, transposase technology, single cell cloning, and stable clone selection to help ensure your biologic is produced efficiently.
We are committed to providing you peace of mind with our fully cGMP-complaint cell line and comprehensive regulatory support to help ensure your biologic meets stringent quality standards while minimizing regulatory delays during later stage of manufacturing.
Utilization of high-throughput equipment, including the Beacon™ and Ambr™ 250 system, our robust CLD platform enables rapid cell line generation, to help speed up your biologic’s path from discovery to commercial launch without compromising quality.